15-Apr-2026 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter 2026 financial results on Wednesday, May 6, 2026, after the close of the U.S. financial markets. Acadias management team will also host a conference call and webcast on May 6, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadias website, acadia.com under the investors section and will be archived there until August 15, 2026. The conference call
12-Mar-2026 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:00 a.m. Eastern Time. A live webcast of Acadias fireside chat will be accessible on the companys website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceuticals Acadia
25-Feb-2026 3:05 PM CST - Business Wire Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the fourth quarter and full year ended December 31, 2025. Acadia closed 2025 with another strong quarter, capping a milestone year in which we surpassed $1 billion in annual revenue for the first time, said Catherine Owen Adams, Chief Executive Officer. NUPLAZID had another strong quarter driven by underlying volume growth, reflecting continued momentum in the business. In the fo
23-Feb-2026 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: TD Cowen's 46th Annual Health Care Conference Fireside Chat: Monday, March 2, 2026 at 11:10 a.m. Eastern Time in Boston, MA The Citizens Life Sciences Conference Fireside Chat: Wednesday, March 11, 2026 at 1:05 p.m. Eastern Time in Miami Beach, FL Live webcasts will be accessible on the companys website, acadia.com, under the investors section
4-Feb-2026 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, after the close of the U.S. financial markets. Acadias management team will also host a conference call and webcast on February 25, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadias website, acadia.com under the investors section and will be archived there until May 24, 20
13-Jan-2026 8:00 AM CST - Business Wire Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's neurological and rare disease drug candidates, which will be discussed today during a presentation by Catherine Owen Adams, Chief Executive Officer, at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. 2026 marks a pivotal year for Acadia as we advance our strategy built for sustained growth and pipeline advancement, said Catherin
18-Dec-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive Officer will represent the company in a session scheduled on Tuesday, January 13, 2026, at 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time. A live webcast of Acadias presentation will be accessible on the companys website, acadia.com, under the investors section and an archi
20-Nov-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Participate in Citis 2025 Global Healthcare Conference Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Citis 2025 Global Healthcare Conference on Tuesday, December 2, 2025 at 9:45 a.m. Eastern Time. A live webcast of Acadias fireside chat will be accessible on the companys website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceutical
5-Nov-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2025. Acadia delivered another strong quarter, generating total revenue of $278.6 million, said Catherine Owen Adams, Chief Executive Officer. NUPLAZID achieved record sales of $177.5 million representing a significant inflection driven by an acceleration in new prescriptions. DAYBUE delivered $101.1 million in sales, driven by the expansion o
15-Apr-2026 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter 2026 financial results on Wednesday, May 6, 2026, after the close of the U.S. financial markets. Acadias management team will also host a conference call and webcast on May 6, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadias website, acadia.com under the investors section and will be archived there until August 15, 2026. The conference call
12-Mar-2026 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:00 a.m. Eastern Time. A live webcast of Acadias fireside chat will be accessible on the companys website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceuticals Acadia
25-Feb-2026 3:05 PM CST - Business Wire Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the fourth quarter and full year ended December 31, 2025. Acadia closed 2025 with another strong quarter, capping a milestone year in which we surpassed $1 billion in annual revenue for the first time, said Catherine Owen Adams, Chief Executive Officer. NUPLAZID had another strong quarter driven by underlying volume growth, reflecting continued momentum in the business. In the fo
23-Feb-2026 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: TD Cowen's 46th Annual Health Care Conference Fireside Chat: Monday, March 2, 2026 at 11:10 a.m. Eastern Time in Boston, MA The Citizens Life Sciences Conference Fireside Chat: Wednesday, March 11, 2026 at 1:05 p.m. Eastern Time in Miami Beach, FL Live webcasts will be accessible on the companys website, acadia.com, under the investors section
4-Feb-2026 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, after the close of the U.S. financial markets. Acadias management team will also host a conference call and webcast on February 25, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadias website, acadia.com under the investors section and will be archived there until May 24, 20
13-Jan-2026 8:00 AM CST - Business Wire Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's neurological and rare disease drug candidates, which will be discussed today during a presentation by Catherine Owen Adams, Chief Executive Officer, at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. 2026 marks a pivotal year for Acadia as we advance our strategy built for sustained growth and pipeline advancement, said Catherin
18-Dec-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive Officer will represent the company in a session scheduled on Tuesday, January 13, 2026, at 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time. A live webcast of Acadias presentation will be accessible on the companys website, acadia.com, under the investors section and an archi
20-Nov-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Participate in Citis 2025 Global Healthcare Conference Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Citis 2025 Global Healthcare Conference on Tuesday, December 2, 2025 at 9:45 a.m. Eastern Time. A live webcast of Acadias fireside chat will be accessible on the companys website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceutical
5-Nov-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2025. Acadia delivered another strong quarter, generating total revenue of $278.6 million, said Catherine Owen Adams, Chief Executive Officer. NUPLAZID achieved record sales of $177.5 million representing a significant inflection driven by an acceleration in new prescriptions. DAYBUE delivered $101.1 million in sales, driven by the expansion o
